Prediction-FREE Neoantigen Validation Enables Personalized Cancer Therapeutics

Prediction-FREE Neoantigen Validation Enables Personalized Cancer Therapeutics

2021–Direct Quantification of Neoantigens Like Never Before — published on Science and Science Immunology

Genetic changes in human genome are the driving force for all cancers. Different patients have different sets of mutation profiles even when the patients all have the same disease. For decades, doctors, cancer scientists, and pharmaceutical companies have been working tirelessly trying to find a way to treat each person’s unique disease in a highly personalized way that will reach the maximum treatment efficacy with the lowest side effects. Complete Omics, working with leaders in cancer therapeutics, has developed two applications based on our Valid-NEO pipeline through which we clearly saw personalized therapeutic targets on the cancer cell surface before adopting a highly specific treatment, for here bispecific antibodies.

Two papers describing our new technologies are puslished on Science (Ref. 1) and Science Immunology (Ref. 2).  Our pipeline has been reported by GenomeWeb (Ref. 3)

  1. Publication: Bispecific antibodies targeting mutant RAS neoantigens.
  2. Publication: Targeting a neoantigen derived from a common TP53 mutation.
  3. Selected Media: Complete Omics Looks to Raise New Funds, Expand Product Menu for Targeted Proteomics Tech | Genomeweb
Follow by Email
Facebook
Twitter
LinkedIn